Tick-Borne Encephalitis Vaccine (TBE)

Vaccine Description	TICOVAC™ Inactivated Contains human serum albumin, protamine sulfate, trace amounts of neomycin and gentamicin See package insert	
Dose & Route	Dose: 0.25 mL Route: IM (Use IM precautions for persons with bleeding disorders or receiving anticoagulant therapy)	
Indications	Individuals 1 – 15 years of age Recommended for people who are living or traveling overseas to a tick-borne encephalitis (TBE) endemic area and will extensive exposure to ticks based on their planned outdoor activities and itinerary.	
Administration Schedule	Dose	Recommended Interval
Primary Schedule	1	Day 0
	2	1-3 months after first vaccination
	3	5-12 months after second vaccination
Booster	4	At least 3 years after completion of primary immunization series if ongoing exposure or re-exposure to TBEV is expected
Contraindications	Severe allergic reaction (e.g. anaphylaxis) to any component of TICOVAC	

Tick-Borne Encephalitis Vaccine (TBE) (Continued)

Precautions	Complete the primary immunization series at least 1 week prior to potential exposure to tick-borne encephalitis virus (TBEV) Some individuals with altered immunocompetence may have reduced immune response Vaccination with TICOVAC™ may not protect all individuals There are no adequate and well-controlled studies of TICOVAC™ in pregnant women.	
Special Considerations	Bring vaccine to room temperature before administration. Shake well prior to administration to thoroughly mix the vaccine suspension. After shaking, the vaccine should be a homogenous off-white, opalescent suspension. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer if particulate matter or discoloration remains after shaking.	
VIS: Currently a VIS is not available from the CDC, patient education material		

available at www.health.mil/tbe. When VIS becomes available it will be provided to

all patients prior to vaccination.